Literature DB >> 6969547

Abnormal product of corneal explants from patients with macular corneal dystrophy.

G K Klintworth, C F Smith.   

Abstract

The glycosaminoglycans synthesized by 5 corneal explants with macular corneal dystrophy were analyzed by sequential degradation using heparitinase (and/or butyl nitrite), chondroitin ABC lyase, chondroitin AC lyase, and keratan sulfate endo-beta-galactosidase. The tissue was first pulse-labeled by incubation in phosphate-buffered saline (pH 7.3) containing 100 muCi/ml 3H-glucosamine and approximately 1000 muCi/ml 35S-sulfate for 1 hour and chased with Eagle's minimum essential medium containing 10% fetal calf serum. Notable differences were detected between the products of these corneal explants with macular corneal dystrophy and controls that were prepared and analyzed in the same manner. As assayed by its susceptibility to keratan sulfate endo-beta-galactosidase degradation, corneal tissue with macular corneal dystrophy incorporated less 35S-sulfate, and usually less 3H-glucosamine, into keratan sulfate than normal corneas. The corneal explants with macular corneal dystrophy also synthesized prominent fractions which eluted from DEAE-Sephacel columns in 0.05 M tris(hydroxymethyl)aminomethane buffer (pH 7.2) with 0.15 M and/or 0.25 M lithium chloride after pronase digestion. Since normal corneas produced small quantities of material with a similar elution profile after preparation and analysis under identical conditions it is possible that the fractions are normal synthetic products of the cornea. The significance of these findings in the pathogenesis of macular corneal dystrophy remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6969547      PMCID: PMC1903571     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Heparan sulfate biosynthesis by embryonic tissues and primary fibroblast populations.

Authors:  G W Conrad; G W Hart
Journal:  Dev Biol       Date:  1975-06       Impact factor: 3.582

2.  Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates.

Authors:  H Saito; T Yamagata; S Suzuki
Journal:  J Biol Chem       Date:  1968-04-10       Impact factor: 5.157

3.  Synthesis of sulfated mucopolysaccharides by chick corneal fibroblasts in vitro.

Authors:  G W Conrad; A Dorfman
Journal:  Exp Eye Res       Date:  1974-05       Impact factor: 3.467

4.  The distribution of 2-acetamido-2-deoxy-D-glucose residues in mammalian heparins.

Authors:  J A Cifonelli; J King
Journal:  Carbohydr Res       Date:  1972-02       Impact factor: 2.104

5.  Histochemistry of corneal macular dystrophy.

Authors:  A Garner
Journal:  Invest Ophthalmol       Date:  1969-10

6.  Structural studies on heparins with unusually high N-acetylglucosamine contents.

Authors:  J A Cifonelli; J King
Journal:  Biochim Biophys Acta       Date:  1973-09-14

7.  Biosynthesis of glycosaminoglycans in bovine cornea. The effet of uridine diphosphate xylose.

Authors:  C Balduini; A Brovelli; A A Cstellani
Journal:  Biochem J       Date:  1970-12       Impact factor: 3.857

8.  The biosynthesis in vitro of keratan sulphate in bovine cornea.

Authors:  C J Handley; C F Phelps
Journal:  Biochem J       Date:  1972-06       Impact factor: 3.857

9.  [Inhibition of corneal metabolism by glucocorticosteroids. An in vitro study (author's transl)]?14Hemmung des Hornhautstoffwechals durch Glukocorticosteroide. Eine in vitro Studie.

Authors:  H Bleckmann; J Wollensak
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1975

10.  Current concepts on the ultrastructural pathogenesis of macular and lattice corneal dystrophies.

Authors:  G K Klintworth
Journal:  Birth Defects Orig Artic Ser       Date:  1971-03
View more
  1 in total

1.  Coexistence of macular corneal dystrophy types I and II in a single sibship.

Authors:  N P Liu; J Baldwin; F Lennon; J M Stajich; E J Thonar; M A Pericak-Vance; G K Klintworth; J M Vance
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.